TrialBMC cancer2026

DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy.

Olga Grishina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.